DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tysabri (Natalizumab) - Published Studies

 
 



Tysabri Related Published Studies

Well-designed clinical trials related to Tysabri (Natalizumab)

Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS. [2012]

Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. [2011.04]

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. [2010.05.15]

Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. [2010.02]

Multiple sclerosis associated fatigue during natalizumab treatment. [2009.10.15]

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. [2009.03]

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. [2009.03]

Cost-Effectiveness Analyses of Natalizumab (Tysabri((R))) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK. [2008]

Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. [2007.12]

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. [2007.10.02]

Health-related quality of life in multiple sclerosis: effects of natalizumab. [2007.10]

Expert opinion: Guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. [2007.07]

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. [2007.05]

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. [2007.04.24]

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. [2007.04.17]

A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis. [2007.03]

Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. [2007.01]

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. [2006.03.02]

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. [2006.03.02]

Natalizumab induction and maintenance therapy for Crohn's disease. [2005.11.03]

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. [2005.10]

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. [2004.06.08]

Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. [2004.04]

Is natalizumab a breakthrough in the treatment of multiple sclerosis? [2003.06]

Natalizumab for active Crohn's disease. [2003.01.02]

A controlled trial of natalizumab for relapsing multiple sclerosis. [2003.01.02]

A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. [1999.03.23]

Well-designed clinical trials possibly related to Tysabri (Natalizumab)

Pharmacological treatment for memory disorder in multiple sclerosis. [2013]

PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. [2010]

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. [2009.03.03]

Monoclonal antibodies in the therapy of multiple sclerosis: an overview. [2008.12]

Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment. [2008]

Newer Therapies for Inflammatory Bowel Disease. [2004.06]

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. [2001.08]

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. [1999.08.11]

Other research related to Tysabri (Natalizumab)

Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. [2014]

Natalizumab: bench to bedside and beyond. [2013]

Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. [2011.11.07]

Natalizumab for relapsing remitting multiple sclerosis. [2011.10.05]

Immune reconstitution inflammatory syndrome in natalizumab-associated PML. [2011.09.13]

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. [2011.08.09]

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. [2011.08]

Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. [2011.07.15]

Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. [2011.06]

Natalizumab and HSV meningitis. [2011.06]

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. [2011.06]

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. [2011.05.31]

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. [2011.05.17]

The toronto observational study of natalizumab in multiple sclerosis. [2011.05]

Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells. [2011.05]

[Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?]. [2011.04]

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society. [2011.04]

[An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis]. [2011.03.16]

Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months. [2011.03]

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. [2011.01]

Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. [2011]

Safety and efficacy of natalizumab in children with multiple sclerosis. [2010.09.07]

Natalizumab dosage suspension: are we helping or hurting? [2010.09]

JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. [2010.09]

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. [2010.09]

Natalizumab drug holiday in multiple sclerosis: poorly tolerated. [2010.09]

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? [2010.08]

Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. [2010.07]

Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. [2010.06.10]

Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy. [2010.06]

A giant MS plaque mimicking PML during natalizumab treatment. [2010.04.15]

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. [2010.04]

Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. [2010.03]

Natalizumab for the treatment of Crohn's disease. [2010]

Progressive multifocal leukoencephalopathy after natalizumab monotherapy. [2009.09.10]

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. [2009.09.10]

Asymptomatic reactivation of JC virus in patients treated with natalizumab. [2009.09.10]

Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy. [2009.09]

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. [2009.08]

Natalizumab in the treatment of multiple sclerosis. [2009.06]

Immunotoxicity profile of natalizumab. [2009.06]

Effects of natalizumab, an alpha4 integrin inhibitor, on the development of Hartley guinea pigs. [2009.04]

The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. [2009.04]

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. [2009.03]

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. [2009.03]

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. [2009.02.03]

alpha4-Integrin antagonism with natalizumab: effects and adverse effects. [2008.12]

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. [2008.10.21]

Effects of natalizumab treatment on Foxp3+ T regulatory cells. [2008.10.06]

Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. [2008.09.02]

Natalizumab: a country-based surveillance program. [2008.09]

Early relapses after the first dose of natalizumab in active multiple sclerosis patients. [2008.09]

Quantitative risk-benefit analysis of natalizumab. [2008.07.29]

Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. [2008.06]

Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy. [2008.06]

[Open use of natalizumab. Neutralising antibodies and clinical data] [2008.06]

Allergic and nonallergic delayed infusion reactions during natalizumab therapy. [2008.05]

Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. [2008.04.30]

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. [2008.04.01]

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. [2008.04.01]

[New drugs; natalizumab] [2008.03.01]

Induction of systemic TNFalpha in natalizumab-treated multiple sclerosis. [2008.03]

Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. [2008.02]

[Natalizumab in multiple sclerosis: the second treatment revolution] [2008.01]

Natalizumab: targeting alpha4-integrins in multiple sclerosis. [2008]

Multiple sclerosis and Natalizumab. [2007.11]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015